Complementary medicine in uro-oncology

被引:1
|
作者
Huebner, Jutta [1 ]
Muecke, Ralph [2 ,3 ]
Micke, Oliver [4 ]
Keinki, Christian [1 ]
机构
[1] Univ Klinikum Jena, Med Klin 2, Klinikum 1, D-07747 Jena, Germany
[2] Standort Bad Kreuznach, Strahlentherapie RheinMainNahe, Bad Kreuznach, Germany
[3] Ruhr Univ, Klin Strahlentherapie & Radioonkol, Bochum, Germany
[4] Franziskus Hosp Bielefeld, Klin Strahlentherapie & Radioonkol, Bielefeld, Germany
来源
UROLOGE | 2021年 / 60卷 / 07期
关键词
Complementary and alternative medicine; Micronutrients; Phytotherapy; Mistletoe; Spirituality; PROSTATE-CANCER TREATMENT; DOUBLE-BLIND; PSA LEVELS; VITAMIN-C; POMEGRANATE; MEN; SPIRITUALITY; RISK; ASSOCIATION; DECISION;
D O I
10.1007/s00120-021-01584-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Complementary and alternative medicine (CAM) is widespread in oncology patients with a user rate of approximately 40-50%. An accompanying supportive effect can arise through improved adherence, especially in long-term (e.g. endocrine) therapies through active patient involvement. When assessing the evidence on frequently requested methods, there is no high-quality evidence that homeopathy or anthroposophy leads to an improved prognosis. Mistletoe therapy can be considered to improve the quality of life, although the data quality is weak. In prostate cancer, pomegranate has an influence on the prostate-specific antigen. It is currently unclear whether this will also result in an improved prognosis. In contrast the evidence on selenium and vitamin D speaks in favor of integration into the aftercare concept. Supplementation is recommended after the serum level has been determined.
引用
收藏
页码:953 / 961
页数:9
相关论文
共 50 条
  • [41] Penile Cancer - A Challenge for Modern Uro-Oncology
    Protzel, C.
    Hakenberg, O. W.
    [J]. AKTUELLE UROLOGIE, 2013, 44 (05) : 363 - 369
  • [42] Advances in Uro-oncology "OncoForurm": The Best of 2013
    Gomez-Veiga, F.
    Alcaraz-Asensio, A.
    Burgos-Revilla, J.
    Cozar-Olmo, J.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (08): : 491 - 498
  • [43] Biobanking: the basis for molecular research in uro-oncology
    Lopez-Beltran, Antonio
    Vidal, Alfredo
    Blanca, Ana
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2013, 66 (05): : 416 - 422
  • [44] Antibody-Drug Conjugates in Uro-Oncology
    Sigorski, Dawid
    Rozanowski, Pawel
    Izycka-Swieszewska, Ewa
    Wiktorska, Katarzyna
    [J]. TARGETED ONCOLOGY, 2022, 17 (03) : 203 - 221
  • [45] Advances in uro-oncology "OncoForum": the best of 2010
    Gomez-Veiga, F.
    Alcaraz-Asensio, A.
    Burgos-Revilla, J.
    Cozar-Olmo, J. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2011, 35 (06): : 315 - 324
  • [46] Promotion of clinical studies in uro-oncology by the AUO
    Rexer, Heidrun
    Hammerer, Peter
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 96 - 97
  • [47] LIQUID BIOPSY: POSSIBILITIES AND LIMITATIONS IN URO-ONCOLOGY
    Lopez-Guerrero, Jose Antonio
    Pastor-Navarro, Belen
    Claramunt-Alonso, Reyes
    Garcia-Flores, Maria
    Rubio-Briones, Y. Jose
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (02): : 203 - 214
  • [48] Advances in Uro-Oncology "Oncoforum": the Best of 2011
    Gomez-Veiga, F.
    Alcaraz-Asensio, A.
    Burgos-Revilla, J.
    Cozar-Olmo, J.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (09): : 507 - 514
  • [50] Is It Worth the Sweat? Prehabilitation in Uro-oncology: A Mini Review
    Sigg, Silvan
    Zeidler, Kristin
    Fankhauser, Christian Daniel
    [J]. EUROPEAN UROLOGY FOCUS, 2024, 10 (01): : 29 - 31